NovaBridge Biosciences
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $632.0K | $-1.6M | $13.8M | $236.4M | $4.3M |
| Cost of Revenue | — | $3.9M | $7.3M | — | — |
| Gross Profit | — | $-5.5M | $6.5M | — | — |
| Gross Margin | — | 354.6% | 47.3% | — | — |
| Operating Expenses | |||||
| Research & Development | $21.4M | $22.5M | $190.3M | $150.9M | $120.7M |
| SG&A Expense | $28.2M | $29.0M | $141.2M | $61.7M | $94.0M |
| Operating Income | $-72.0M | $-53.1M | $-366.4M | $74.2M | $-208.1M |
| Operating Margin | -11,395.1% | 3,422.2% | -2,652.3% | 31.4% | -4,830.1% |
| Interest Expense | $102.0K | $1.0K | $0 | $147.0K | $430.0K |
| Pretax Income | $-82.2M | $-141.1M | $-366.4M | $74.0M | $-208.6M |
| Income Tax Expense | $0 | $103.0K | $-495.0K | $1.9M | — |
| Net Income | $-207.7M | $-371.1M | $-365.9M | $72.2M | $-208.6M |
| Net Margin | -32,868.5% | 23,923.5% | -2,648.7% | 30.5% | -4,840.1% |
| EPS (Basic) | $-1.09 | $-1.96 | $-2.09 | $0.54 | $-1.38 |
| EPS (Diluted) | $-1.09 | $-1.96 | $-2.09 | $0.46 | $-1.38 |
| Shares Outstanding (Basic) | 191.4M | 189.8M | 174.7M | 134.2M | 155.0M |
| Shares Outstanding (Diluted) | 191.4M | 189.8M | 174.7M | 157.2M | 155.0M |
| Dividends Per Share | — | — | — | — | — |